Pharmacokinetics of amikacin in plasma of healthy goats after intravenous injection once daily for three days.
- Author:
Sania NASEEM
1
;
Mudasir SULTANA
;
Rajinder RAINA
;
Nrip Kishore PANKAJ
;
Pawan Kumar VERMA
;
Nasir Ahmad NASIR
;
Azad Ahmad AHANGER
;
Shafiqur RAHMAN
;
Shahid PRAWEZ
Author Information
1. Division of Pharmacology and Toxicology, Faculty of Veterinary Sciences and Animal Husbandry, SKUAST-J, R.S. Pura, Jammu-181 102 (J&K), India. shahidprawez@gmail.com
- Publication Type:Original Article
- Keywords:
amikacin;
intravenous bolus injection;
pharmacokinetics;
three days;
10 mg/kg
- MeSH:
Amikacin;
Aminoglycosides;
Body Weight;
Goats;
Gram-Positive Bacteria;
Half-Life;
Injections, Intravenous;
Kanamycin;
Plasma
- From:Korean Journal of Veterinary Research
2011;51(4):253-257
- CountryRepublic of Korea
- Language:English
-
Abstract:
Amikacin is a semisynthetic derivative of kanamycin and primarily active against aerobic Gram-negative-pathogens with limited activity against Gram-positive bacteria. Meager study was reported on pharmacokinetic data on multi-days administration of amikacin. Hence, pharmacokinetics study was done in five clinically healthy goats (n = 5), after intravenous bolus injection of amikacin sulfate at the dose rate of 10 mg/kg body weight daily for three consecutive days. The amikacin concentrations in plasma and pharmacokinetics-parameters were analyzed by using microbiological assay technique and noncompartmental open-model, respectively. The mean peak plasma concentrations (Mean +/- SD) of amikacin at time zero (Cp0) was 114.19 +/- 20.78 and 128.67 +/- 14.37 microg/mL, on day 1st and 3rd, respectively. The mean elimination half-life (t(1/2)ke) was 1.00 +/- 0.28 h on day 1st and 1.22 +/- 0.29 h on day 3rd. Mean of area under concentration-time curve (AUC(0-->infinity)) was 158.26 +/- 60.10 and 159.70 +/- 22.74 microg.h/mL, on day 1st and 3rd respectively. The total body clearance (ClB) and volume of distribution at steady state (Vdss) on day 1st and 3rd were ClB = 0.07 +/- 0.02 and 0.06 +/- 0.01 L/h.kg and Vdss = 0.10 +/- 0.03 and 0.11 +/- 0.05 L/kg, respectively. No-significant difference was noted in both drug-plasma concentration and pharmacokinetics-parameters, respectively. Amikacin concentration in plasma was found higher up-to 4 h and 6 h onward on down-ward trends favour to reduce toxicity. Which also support the pharmacokinetic-pharmacodynamic way of dosing of aminoglycosides and hence, amikacin may be administered 10 mg/kg intravenously daily to treat principally Gram-negative pathogens and limitedly Gram-positive-pathogens.
